

PHARMACY POLICY STATEMENT North Carolina Marketplace

| | |
|------------------|----------------------------------|
| DRUG NAME | Evkeeza (evinacumab-dgnb) |
| BENEFIT TYPE | Medical |
| STATUS | Prior Authorization Required |

Evkeeza, approved by the FDA in 2021, is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first ANGPTL3 inhibitor to be approved. ANGPTL3 is a protein in the liver that has a role in regulating lipid metabolism. Its inhibition reduces LDL, HDL, and triglycerides.

Evkeeza (evinacumab-dgnb) will be considered for coverage when the following criteria are met:

Homozygous Familial Hypercholesterolemia (HoFH)

For **initial** authorization:

1. Member is at least 5 years of age; AND
2. Medication must be presc [()]idered-7()-7/y05826 44.2 296.38 12.025 re W* 7(L)-14(D)8c2 0 1 205.(



For reauthorization: